3-(2H-indazol-3-yl)-N-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine
C17H24BN3O2 — CID 170814621
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-(2H-indazol-3-yl)-N-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine
3-(2H-indazol-3-yl)-N-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine (PubChem CID 170814621) has the molecular formula C17H24BN3O2 and a molecular weight of 313.21 g/mol. Its IUPAC name is 3-(2H-indazol-3-yl)-N-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine.
Molecular Properties
| Compound Name | 3-(2H-indazol-3-yl)-N-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine |
|---|---|
| PubChem CID | 170814621 |
| Molecular Formula | C17H24BN3O2 |
| Molecular Weight | 313.21 g/mol |
| Exact Mass | 313.20 |
| IUPAC Name | 3-(2H-indazol-3-yl)-N-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-amine |
| SMILES | CNCC(=Cc1[nH]nc2ccccc12)B1OC(C)(C)C(C)(C)O1 |
| InChI | InChI=1S/C17H24BN3O2/c1-16(2)17(3,4)23-18(22-16)12(11-19-5)10-15-13-8-6-7-9-14(13)20-21-15/h6-10,19H,11H2,1-5H3,(H,20,21) |
| InChIKey | GXVLSCIAJJQESW-UHFFFAOYSA-N |
| XLogP | 2.80 |
| TPSA | 59.17 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 23 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 313.21 |
| LogP ≤ 5 | 2.80 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'heavy_metal', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 170814621 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.